Literature DB >> 26202013

Long-term hormonal follow-up after human Puumala hantavirus infection.

Terhi Partanen1, Minna Koivikko1, Päivi Leisti1, Pasi Salmela1, Eija Pääkkö2, Ari Karttunen2, Harri Sintonen3, Leila Risteli4, Nina Hautala5, Olli Vapalahti6, Antti Vaheri6, Heikki Kauma1, Timo Hautala1.   

Abstract

OBJECTIVE: Nephropathia epidemica (NE) is a haemorrhagic fever with renal syndrome (HFRS) caused by Puumala hantavirus (PUUV). Pituitary haemorrhage and hypopituitarism may complicate recovery from acute NE.
DESIGN: Forty-seven of our recent cohort of 58 NE patients volunteered to be re-examined in order to estimate the burden of hormonal deficiency 4 to 8 years after the acute illness. Two patients had suffered from pituitary haemorrhage, but many others exhibited pituitary oedema during their acute infection. In this study, we searched for symptoms of hormonal deficiency, performed hormonal laboratory screening, and most patients underwent pituitary MRI examination.
RESULTS: The pituitary size had diminished in all patients in whom MRI was performed (P < 0·001). One patient with acute phase haemorrhage had made a complete recovery while the other continued to require hormonal substitution. In addition, hormonal laboratory abnormalities were observed in nine other patients; these being attributable to several reasons, for example independent peripheral hormonal diseases, side effects of medication or other secondary causes such as obesity. None of them had signs of late-onset pituitary insufficiency caused by their previous NE. Health-related quality of life (mean and median 15D score) of patients was comparable to that of age-standardized general population.
CONCLUSIONS: None of our patients had developed obvious late-onset hypopituitarism despite of the fact that pituitary gland can be affected during acute NE. We recommend requesting a history of hantavirus infection whenever the possibility of pituitary dysfunction is suspected at least in patients originating from regions with high NE infection rate.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202013     DOI: 10.1111/cen.12863

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Hemorrhagic fever with renal syndrome accompanied by panhypopituitarism and central diabetes insipidus: a case report.

Authors:  Hee Jung Ahn; Jong-Hoon Chung; Dong-Min Kim; Na-Ra Yoon; Choon-Mee Kim
Journal:  J Neurovirol       Date:  2018-03-05       Impact factor: 2.643

2.  Autoimmune polyendocrinopathy and hypophysitis after Puumala hantavirus infection.

Authors:  Marlene Tarvainen; Satu Mäkelä; Jukka Mustonen; Pia Jaatinen
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-11-04

Review 3.  Hypopituitarism after Orthohantavirus Infection: What is Currently Known?

Authors:  Soerajja Bhoelan; Thomas Langerak; Danny Noack; Linda van Schinkel; Els van Nood; Eric C M van Gorp; Barry Rockx; Marco Goeijenbier
Journal:  Viruses       Date:  2019-04-10       Impact factor: 5.048

Review 4.  Hantavirus Research in Finland: Highlights and Perspectives.

Authors:  Antti Vaheri; Heikki Henttonen; Jukka Mustonen
Journal:  Viruses       Date:  2021-07-26       Impact factor: 5.048

Review 5.  Central Nervous System and Ocular Manifestations in Puumala Hantavirus Infection.

Authors:  Nina Hautala; Terhi Partanen; Anna-Maria Kubin; Heikki Kauma; Timo Hautala
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

6.  Hormonal Defects Are Common during Puumala Hantavirus Infection and Associate with Disease Severity and Biomarkers of Altered Haemostasis.

Authors:  Marlene Tarvainen; Satu Mäkelä; Outi Laine; Ilkka Pörsti; Sari Risku; Onni Niemelä; Jukka Mustonen; Pia Jaatinen
Journal:  Viruses       Date:  2021-09-13       Impact factor: 5.048

7.  Long-Term Consequences of Puumala Hantavirus Infection.

Authors:  Jukka Mustonen; Antti Vaheri; Ilkka Pörsti; Satu Mäkelä
Journal:  Viruses       Date:  2022-03-14       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.